·: ·6617This review is concerned primarily with the papers that have appeared since the end of 1972 subsequent to the material in the book by Nahas (1) and the review volumes edited by Mechoulam (2) and by Gibbins et al (3). The main new developments have been in the biochemistry of cannabis metabolites, in cellular and toxicological effects, and in a widening of human studies.
CHEMICAL ASPECTSStructure-Action Relationships (4,5,6) Variations in potency among cannabinoids by a factor of over 2000 are now recorded, which allow considerable scope for structure-action studies. But estimates of relative potency remain difficult to make because of the variability among subjects (whether animals or humans). At a deeper level, little work has been done to assess how far variations in potency reflect differences in pharmacokinetics or in metabo lism (with possible formation both of active and inactive metabolites), as against differences in effect at the ultimate site(s) of action. In addition, many of the structures involved have several isomers and are usually tested as mixtures. Finally, pharmacological study has not been sufficiently detailed to exclude major differences in type of action between the various substances. This may be important, since trial of I, l-dimethylheptyl-�3-THC (DMHP) in man showed that, while it produces pronounced tachycardia and hypotension in man, it has no psychic effect (7). The same may be true of other compounds tested only in animals.Subject to these qualifications, the following provisional generalizations may be made, characterizing the tetrahydrocannabinol (THC) molecule as possessing three rings, terpenoid, pyran, and aromatic and using the terpenoid nomenclature.